tbuckley/cabot-search huggingface dataset:
Comparative outcomes of extracorporeal shockwave therapy for shoulder tendinitis or partial tears of the rotator cuff in athletes and non-athletes
Authors: Haoqiang Huang, Feng Xu, Xinting Feng, Zhiwen Luo, Qing Wang
Journal: International Journal of Surgery (2023)

aDepartment of orthopedics, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu Province, China bDepartment of Sports Medicine, Huashan Hospital, Fudan University, Shanghai, China Wang Qing Haoqiang Huang and Feng Xu: These authors equally contribute to the works. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of orthopedics, Kunshan Hospital of Traditional Chinese Medicine, Zuchongzhi Road No.388, Kunshan, Jiangsu Province, China. E-mail address: [email protected] (Q. Wang). *Corresponding author. Address: Department of Sports Medicine, Huashan Hospital, Fudan University, Shanghai, China. E-mail address: [email protected] (Z. Luo). This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0/
Interploidy Introgression Shaped Adaptation during the Origin and Domestication History of <i>Brassica napus</i>
Authors: Tianpeng Wang, Aalt D J van Dijk, Johan Bucher, Jianli Liang, Jian Wu, Guusje Bonnema, Xiaowu Wang
Journal: Molecular Biology and Evolution (2023)

Polyploidy is recurrent across the tree of life and known as an evolutionary driving force in plant diversification and crop domestication. How polyploid plants adapt to various habitats has been a fundamental question that remained largely unanswered. Brassica napus is a major crop cultivated worldwide, resulting from allopolyploidy between unknown accessions of diploid B. rapa and B. oleracea. Here, we used whole-genome resequencing data of accessions representing the majority of morphotypes and ecotypes from the species B. rapa, B. oleracea, and B. napus to investigate the role of polyploidy during domestication. To do so, we first reconstructed the phylogenetic history of B. napus, which supported the hypothesis that the emergence of B. napus derived from the hybridization of European turnip of B. rapa and wild B. oleracea. These analyses also showed that morphotypes of swede and Siberian kale (used as vegetable and fodder) were domesticated before rapeseed (oil crop). We next observed that frequent interploidy introgressions from sympatric diploids were prominent throughout the domestication history of B. napus. Introgressed genomic regions were shown to increase the overall genetic diversity and tend to be localized in regions of high recombination. We detected numerous candidate adaptive introgressed regions and found evidence that some of the genes in these regions contributed to phenotypic diversification and adaptation of different morphotypes. Overall, our results shed light on the origin and domestication of B. napus and demonstrate interploidy introgression as an important mechanism that fuels rapid diversification in polyploid species.
The impact of <scp>US</scp> abortion policy on rheumatology clinical practice: a cross‐sectional survey of rheumatologists
Authors: Bonnie L. Bermas, Irene Blanco, Rosalind Ramsey‐Goldman, Ashira D. Blazer, Megan E. B. Clowse, Cuoghi Edens, Greer Donley, Leslie Pierce, Catherine Wright, Mehret Birru Talabi
Journal: Arthritis & Rheumatology (2023)

image
Right-Sizing Models of Genetic Cancer Predisposition Testing
Authors: Huma Q. Rana, Judy E. Garber
Journal: JAMA Oncology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Targeted dosing of anti‐thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single‐arm, phase 2 trial
Authors: Haitao Wang, Nan Wang, Lili Wang, Jishan Du, Fei Li, Yangliu Shao, Bo Peng, Songhua Luan, Lu Wang, Xiangshu Jin, Chunji Gao, Liping Dou, Daihong Liu
Journal: American Journal of Hematology (2023)

Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence. To investigate the optimal dosing of ATG, we established a targeted dosing strategy based on ATG concentration monitoring for haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). The aim of this phase 2 trial is to evaluate the safety and efficacy of the ATG-targeted dosing strategy in adult unmanipulated haplo-PBSCT. ATG was administered for 4 days (-5 days to -2 days) during conditioning. The ATG doses on -3 days and -2 days were adjusted by our dosing strategy to achieve the optimal ATG exposure. The primary endpoint was CMV reactivation on +180 days. Between December 2020 and January 2022, 66 haplo-PBSCT patients were enrolled and 63 of them were evaluable with a median follow-up of 632 days. The cumulative incidence of CMV reactivation was 36.7% and that of EBV was 58.7%. The 1-year disease-free survival was 82.5%, overall survival was 92.1%, and CD4+ T-cell reconstruction on +100 days was 76.8%. The most common severe regimen-associated toxicities (> grade 3) were infections (51.5%) and gastrointestinal toxicity (25.5%). A total of 102 haplo-PBSCT patients who received the conventional fixed ATG dose (cumulative 10 mg/kg) comprised historical control. The outcomes in historical control were inferior to those of phase 2 trial cohort (CMV reactivation: 70.8%, p < .001; EBV reactivation: 76.0%, p = .024; CD4 + T-cell reconstruction: 54.1%, p = .040). In conclusion, ATG-targeted dosing strategy reduced CMV/EBV reactivation and improved survival without increasing GVHD after haplo-PBSCT. These advantages may be associated with accelerated immune reconstitution.
Germline <scp><i>DDX41</i></scp> mutant predisposition syndromes: Slow driver states to hematological malignancies
Authors: Timothy M. Chlon, Mrinal M. Patnaik
Journal: American Journal of Hematology (2023)

Mrinal M Patnaik has received research funding from StemLine Pharmaceuticals, Kura Oncology, and Epigenetix. He has served on the advisory board for CTI pharmaceuticals. No original data contained in the manuscript.
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial
Authors: Elizabeth M. Swisher, Nadine Rayes, Deborah Bowen, Christine B. Peterson, Barbara M. Norquist, Tara Coffin, Kathleen Gavin, Deborah Polinsky, Jamie Crase, Jamie N. Bakkum-Gamez, Stephanie V. Blank, Mark F. Munsell, Denise Nebgen, Gini F. Fleming, Olufunmilayo I. Olopade, Sherman Law, Alicia Zhou, Douglas A. Levine, Alan D’Andrea, Karen H. Lu
Journal: JAMA Oncology (2023)

Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress.
ChatGPT or LLM in next-generation drug discovery and development: Pharmaceutical and biotechnology companies can make use of the artificial intelligence (AI)-based device for a faster way of drug discovery and development
Authors: Soumen Pal, Manojit Bhattacharya, Md. Aminul Islam, Chiranjib Chakraborty
Journal: International Journal of Surgery (2023)

Pal, Soumen PhD; Bhattacharya, Manojit PhD; Islam, Md. Aminul; Chakraborty, Chiranjib PhD Author Information
Reported Risky Alcohol Use Among US Adults Prescribed 3 Classes of Chronic Alcohol–Interactive Medications
Authors: Eden Y. Bernstein, Travis P. Baggett, Timothy S. Anderson
Journal: JAMA (2023)

This study uses data from the 2013–March 2020 National Health and Nutrition Examination Survey to assess contemporary patterns of risky alcohol use among adults taking high-risk alcohol-interactive medications (benzodiazepine receptor agonists, opioids, and antiepileptics).
Serum autoantibodies and the risk of cancer in systemic sclerosis over time
Authors: Maria De Santis, Antonio Tonutti, Francesca Motta, Stefano Rodolfi, Natasa Isailovic, Carlo Selmi
Journal: Arthritis & Rheumatology (2023)

Disclosure form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Metastases-Targeting Radiotherapy and ADT—Reply
Authors: Alexander D. Sherry, Paul G. Corn, Chad Tang
Journal: JAMA Oncology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Pilot Trial Characteristics, Postpilot Design Modifications, and Feasibility of Full-Scale Trials
Authors: Xiangji Ying, Stephan Ehrhardt
Journal: JAMA Network Open (2023)

Importance Pilot trials often lead to study design changes in subsequent full-scale trials. Yet, it remains unclear whether these modifications improve the feasibility of the larger trial. Objective To compare feasibility estimates between pilot and full-scale trials and identify pilot trial characteristics and modifications associated with equivalent or improved feasibility in the full-scale trial. Design, Setting, and Participants This cohort study used pilot trials published between January 2005 and December 2018 and their corresponding full-scale trials. PubMed was searched for trials on February 19, 2022. Exposures Pilot trial characteristics and postpilot trial design modifications. Main Outcomes and Measures The outcome of interest was difference in 3 feasibility parameters: successful screening probability, enrollment rate, and retention probability. These metrics were defined as equivalent or improved if the full-scale trial’s estimate was within or exceeding 10% of the pilot trial’s estimate. Results A total of 249 pairs of pilot and full-scale trials were analyzed, with 43%, 77%, and 82% of full-scale trials having equivalent or improved successful screening probabilities, enrollment rates, and retention probabilities, respectively. When pilot trials used feasibility progression criteria (relative risk [RR], 1.94; 95% CI, 1.02-5.97) and maintained masking for participants (RR, 1.82; 95% CI, 1.04-4.33) or health care practitioners (RR, 1.81; 95% CI, 1.03-3.97) consistent with the full-scale trial, the likelihood of achieving equivalent or improved screening success in full-scale trials increased. Increasing study sites after the pilot was associated with higher likelihood of equivalent or improved enrollment rates (RR, 1.03; 95% CI, 1.01-1.08). Adding extra content to the intervention (RR, 0.82; 95% CI, 0.66-0.98), changing to active control (RR, 0.74; 95% CI, 0.48-0.99), administrating the control treatment more frequently (RR, 0.60; 95% CI, 0.29-0.93), different follow-up lengths (RR, 0.85; 95% CI, 0.73-0.97), and more follow-up visits (RR, 0.86; 95% CI, 0.75-0.98) were associated with lower likelihood of equivalent or improved retention probability in the full-scale trial. Conclusions and relevance In this cohort study of pilot and full-scale trial pairs, pilot trial characteristics and postpilot modifications had varying associations with full-scale trial’s feasibility. If full-scale trials planned for masking, it was desirable to use it in the pilot. Modifications increasing participant burden might decrease full-scale trial feasibility. Trialists and funders should consider both pilot trial data and proposed design changes when assessing full-scale trials.
Is ChatGPT a qualified thoracic surgeon assistant?
Authors: Zhangyi Dai, Xiaolong Zhang, Cheng Shen, Yikai Xing, Qiang Pu
Journal: International Journal of Surgery (2023)

Dai, Zhangyi MD; Zhang, Xiaolong MD; Shen, Cheng MD; Xing, Yikai MD; Pu, Qiang MD Author Information
Multimodal Imaging of Pancreatic Cancer Microenvironment in Response to an Antiglycolytic Drug
Authors: Elnaz Sheikh, Kirti Agrawal, Sanjit Roy, David Burk, Fabrizio Donnarumma, Young H. Ko, Praveen Kumar Guttula, Nrusingh C. Biswal, Hem D. Shukla, Manas Ranjan Gartia
Journal: Advanced Healthcare Materials (2023)

Lipid metabolism and glycolysis play crucial roles in the progression and metastasis of cancer, and the use of 3-bromopyruvate (3-BP) as an antiglycolytic agent has shown promise in killing pancreatic cancer cells. However, developing an effective strategy to avoid chemoresistance requires the ability to probe the interaction of cancer drugs with complex tumor-associated microenvironments (TAMs). Unfortunately, no robust and multiplexed molecular imaging technology is currently available to analyze TAMs. In this study, the simultaneous profiling of three protein biomarkers using SERS nanotags and antibody-functionalized nanoparticles in a syngeneic mouse model of pancreatic cancer (PC) is demonstrated. This allows for comprehensive information about biomarkers and TAM alterations before and after treatment. These multimodal imaging techniques include surface-enhanced Raman spectroscopy (SERS), immunohistochemistry (IHC), polarized light microscopy, second harmonic generation (SHG) microscopy, fluorescence lifetime imaging microscopy (FLIM), and untargeted liquid chromatography and mass spectrometry (LC-MS) analysis. The study reveals the efficacy of 3-BP in treating pancreatic cancer and identifies drug treatment-induced lipid species remodeling and associated pathways through bioinformatics analysis.
Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer
Authors: Hakyoung Kim, Tae In Yoon, Seonok Kim, Sae Byul Lee, Jisun Kim, Il Yong Chung, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Sungchan Gwark, Jeong Kyeung Kim, Hee Jeong Kim
Journal: JAMA Network Open (2023)

Importance Contralateral breast cancer (CBC) is the most frequently diagnosed primary cancer in patients with breast cancer. Although many studies have reported survival after the development of CBC, results have been inconsistent. Objective To investigate whether the development of CBC is associated with survival among patients with breast cancer. Design, Setting, and Participants This cohort study was conducted at the Asan Medical Center, Korea, among patients who were diagnosed with primary unilateral, nonmetastatic, stage 0 to III breast cancer between 1999 and 2013 and followed up through 2018. The median (IQR) follow-up was 107 (75-143) months. Patients were categorized into CBC and no-CBC groups by whether they developed CBC during the follow-up period. Data were analyzed from November 2021 to March 2023. Exposure Development of CBC. Main outcomes and measures Survival rates of CBC and no-CBC groups were compared using a time-dependent Cox proportional hazard model in the entire study population and in subgroup analyses by interval of CBC development and subtype of the primary breast cancer. Results Among 16 251 patients with breast cancer (all Asian, specifically Korean; mean [SD] age, 48.61 [10.06] years), 418 patients developed CBC. There was no significant difference in overall survival between CBC and no-CBC groups (hazard ratio, 1.166; 95% CI, 0.820-1.657). Patients who developed CBC within 1.5 years after the surgery of the primary breast cancer had a higher risk for overall death during the study period (hazard ratio, 2.014; 95% CI, 1.044-3.886), and those who developed CBC after 1.5 years showed no significant difference in survival compared with the no-CBC group. Patients with hormone receptor (HR)–positive and human epidermal growth factor receptor 2 ( ERBB2 , formerly HER2)–negative breast cancer had a higher risk for overall death in the CBC group (hazard ratio, 1.882; 95% CI, 1.143-3.098) compared with the no-CBC group. Conclusions and Relevance This study found that development of CBC in patients with breast cancer was not associated with survival but that early development of CBC after diagnosis of the primary breast cancer or development of CBC in patients with HR-positive/ ERBB2 -negative breast cancer was associated with survival. These results may provide valuable information for patients seeking advice on opting for contralateral prophylactic mastectomy.
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
Authors: Brett King, Jerry Shapiro, Manabu Ohyama, Alexander Egeberg, Bianca Maria Piraccini, Brittany Craiglow, Rodney Sinclair, Yun-Fei Chen, Wen-Shuo Wu, Yuxin Ding, Najwa Somani, Yves Dutronc
Journal: British Journal of Dermatology (2023)

Abstract Background Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. Objectives To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. Methods The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]. Patients randomized to baricitinib 4 mg or 2 mg retained their treatment allocation for 52 weeks. Based on patterns identified through growth mixture modelling (GMM), patients were categorized into responder subgroups according to when they first achieved ≥ 30% improvement from baseline in SALT score (SALT30). For each responder subgroup, trajectories of response (i.e. achievement of a SALT score ≤ 20, SALT score ≤ 10 and ≥ 50% change from baseline in SALT score) and baseline disease characteristics are reported. Results Respectively, 515 and 340 patients were randomized to once-daily baricitinib 4 mg and 2 mg at baseline; 69% and 51%, respectively, achieved SALT30 at least once by week 52. Based on GMM findings, we identified three responder subgroups: early (SALT30 by week 12), gradual (SALT30 after week 12–week 36) and late (SALT30 after week 36–week 52). The proportions of early, gradual and late responders and nonresponders were, respectively, 33%, 28%, 8% and 31% among patients treated with baricitinib 4 mg, and 20%, 23%, 9% and 49%, respectively, among those treated with baricitinib 2 mg. Early responders had a shorter trajectory to maximal clinical outcomes (e.g. &amp;gt; 78% achieved a SALT score ≤ 20 by week 36) vs. gradual or late responders. Early responders were more frequent among patients with baseline severe AA (SALT score 50 to &amp;lt; 95) vs. very severe AA (SALT score 95–100). Overall, responders (early to late) were more frequent in patients with short (&amp;lt; 4 years) episodes of hair loss. Conclusions These analyses identified early, gradual and late responder subgroups for scalp hair regrowth in baricitinib-treated patients with severe AA, and that these subgroups are influenced by baseline characteristics. Findings from these analyses will help to inform treatment expectations for scalp hair regrowth.
Catalyzing Generation and Stabilization of Oxygen Vacancies on CeO<sub>2−x</sub> Nanorods by Pt Nanoclusters as Nanozymes for Catalytic Therapy
Authors: Jiankang Zhang, Yu Yang, Fengmin Qin, Tingting Hu, Xinshuo Zhao, Shichao Zhao, Yueqiang Cao, Zhe Gao, Zhan Zhou, Ruizheng Liang, Chaoliang Tan, Yong Qin
Journal: Advanced Healthcare Materials (2023)

Abstract Although CeO 2 nanomaterials have been widely explored as nanozymes for catalytic therapy, they still suffer from relatively low activities. Herein, the catalyzing generation and stabilization of oxygen vacancies on CeO 2 nanorods by Pt nanoclusters via H 2 gas reduction under mild temperature (350 °C) to obtain Pt/CeO 2− x , which can serve as a highly efficient nanozyme for catalytic cancer therapy, is reported. The deposited Pt on CeO 2 by the atomic layer deposition technique not only can serve as the catalyst to generate oxygen vacancies under mild temperature reduction through the hydrogen spillover effect, but also can stabilize the generated oxygen vacancies. Meanwhile, the oxygen vacancies also provide anchoring sites for Pt forming strong metal‐support interactions and thus preventing their agglomerations. Importantly, the Pt/CeO 2− x reduced at 350 °C (Pt/CeO 2− x ‐350R) exhibits excellent enzyme‐mimicking catalytic activity for generation of reactive oxygen species (e.g., ·OH) as compared to other control samples, including CeO 2 , Pt/CeO 2 , and Pt/CeO 2− x reduced at other temperatures, thus achieving excellent performance for tumor‐specific catalytic therapy to efficiently eliminate cancer cells in vitro and ablate tumors in vivo. The excellent enzyme‐mimicking catalytic activity of Pt/CeO 2− x ‐350R originates from the good catalytic activities of oxygen vacancy‐rich CeO 2− x and Pt nanoclusters.